Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of QL1205 vs Lucentis in Wet AMD
NCT03312283Phase 1Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Dec 2017
- Primary completion
- Apr 2019
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of QL1205 in exudative macular degeneration (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Safety of QL1205 at 85 days. Started Dec 2017; status: completed.
02
Drugs
QL1205
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT03312283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03312283.